LDL-C升高的全球负担:2023年全球疾病负担研究结果
该研究基于2023年全球疾病负担研究,采用比较风险评估方法,在204个国家和地区估计1990至2023年LDL-C升高(相对于35-54 mg/dL)归因于缺血性心脏病和缺血性卒中的死亡与DALYs。2023年LDL-C升高导致360万死亡(95%UI 2.2-5.4百万;占全球死亡6.0%)和9070万DALYs(95%UI 58.9-123.3百万;占3.2%)。尽管全球全年龄段率保持稳定,年龄标化死亡率和DALY率自1990年分别下降45.6%和39.5%。2023年年龄标化LDL-C归因DALY率东欧最高、高收入亚太地区最低,全球三分之一的LDL-C负担发生在印度和中国。人口增长和老龄化驱动负担增加,LDL-C暴露和风险删除DALY率存在显著区域差异,负担向中等社会人口指数环境转移。
要点
- 2023年LDL-C升高导致360万死亡(95%UI 2.2-5.4百万;占全球死亡6.0%)和9070万DALYs(95%UI 58.9-123.3百万;占3.2%)。
- 全球全年龄段LDL-C归因率保持稳定,但年龄标化死亡率和DALY率自1990年分别下降45.6%和39.5%。
- 2023年年龄标化LDL-C归因DALY率东欧最高、高收入亚太地区最低;全球三分之一的LDL-C负担发生在印度和中国。
- 人口增长和老龄化驱动LDL-C负担增加,负担向中等社会人口指数国家转移。
- 测量和监测差距持续存在,作者认为加强预防、诊断和治疗可及性策略对减轻LDL-C健康负担至关重要。
适用人群与场景
- 25岁及以上成年人,1990至2023年,全球204个国家和地区。
诊断标准与关键阈值
- LDL-C升高定义为相对于35-54 mg/dL的暴露水平。
研究设计与关键结果
- 研究类型:2023年全球疾病负担研究中的比较风险评估,覆盖204个国家和地区;平均LDL-C水平基于161个国家806项研究采用时空高斯过程回归估计;相对风险来自38项随机临床试验的荟萃分析;归因分数按年龄和性别估计,适用于25岁及以上成年人,时间范围为1990至2023年,并报告95%不确定性区间。
- 2023年LDL-C升高导致360万死亡(95%UI 2.2-5.4百万;占全球死亡6.0%)和9070万DALYs(95%UI 58.9-123.3百万;占3.2%)。
- 全球全年龄段率保持稳定;年龄标化死亡率和DALY率自1990年分别下降45.6%和39.5%。
- 2023年年龄标化LDL-C归因DALY率东欧最高、高收入亚太地区最低;全球三分之一的LDL-C负担发生在印度和中国。
- 人口增长和老龄化驱动负担增加,LDL-C暴露和风险删除DALY率存在显著区域差异,负担向中等社会人口指数环境转移。
证据类型、等级与局限
- 证据类型:全球疾病负担研究的比较风险评估。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,加强预防、诊断和治疗可及性策略对减轻LDL-C健康负担至关重要。
- 原文指出测量和监测差距持续存在。
指南或共识出处
- Global Burden of Disease Study 2023
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Elevated low-density lipoprotein cholesterol (LDL-C) is a modifiable risk factor for cardiovascular disease, the leading cause of premature death worldwide. Assessing the LDL-C-related burden is critical for guiding prevention and treatment strategies.
OBJECTIVES: To estimate the global, regional, and national burden of ischemic heart disease and ischemic stroke attributable to elevated LDL-C (relative to 35-54 mg/dL) from 1990 to 2023 and to quantify the contributions of population growth, aging, risk-deleted burden, and exposure changes to burden trends.
DESIGN, SETTING, AND POPULATION: This comparative risk assessment, part of the Global Burden of Disease Study 2023, estimated population-level LDL-C exposure and associated health loss in 204 countries and territories. Mean LDL-C levels were estimated using spatiotemporal gaussian process regression based on 806 studies across 161 countries. Relative risks were derived from meta-analyses of 38 randomized clinical trials. Population-attributable fractions for deaths and disability-adjusted life-years (DALYs) were estimated by age and sex for adults aged 25 years or older from 1990 to 2023, with 95% uncertainty intervals.
EXPOSURE: Population-level LDL-C concentrations.
MAIN OUTCOMES AND MEASURES: Population-attributable fractions, counts, and rates (all ages and age standardized per 100 000) of LDL-C-attributable deaths and DALYs from ischemic heart disease and ischemic stroke, with uncertainty intervals.
RESULTS: In 2023, elevated LDL-C accounted for 3.6 million deaths (95% uncertainty interval, 2.2-5.4 million; 6.0% of global mortality) and 90.7 million DALYs (95% uncertainty interval, 58.9-123.3 million; 3.2% of DALYs). Although global all-ages rates remained stable, age-standardized death and DALY rates decreased by 45.6% and 39.5%, respectively, since 1990. In 2023, age-standardized LDL-C-attributable DALY rates were highest in Eastern Europe and lowest in high-income Asia-Pacific. One-third of the global LDL-C burden occurred in India and China. Population growth and aging drove the increasing burden, with notable regional disparities in LDL-C exposure and risk-deleted DALY rates shifting toward middle-sociodemographic settings.
CONCLUSIONS AND RELEVANCE: Despite declining age-standardized rates, the absolute LDL-C burden has increased since 1990 due to demographic changes and has shifted toward middle-sociodemographic countries. Measurement and surveillance gaps persist. Strengthened prevention, diagnosis, and treatment access strategies are essential to mitigate the health burden of LDL-C.
参考来源
- Razo C, DeCleene NK, Johnson CO, et al. Global Burden of Elevated LDL-C: Findings From the Global Burden of Disease Study 2023. JAMA. 2026. PMID: 42525403. doi:10.1001/jama.2026.8628
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。